Pfizer & BioNTech Consider ‘Future Vaccine Relaunch’ Due to ‘Horrific’ New Covid Variant

Pfizer-BioNTech may be envisioning another way to pad its corporate profits, which have been driven sky high due in part to mandates and failed predictions, such as that the ‘vaccines’ would ‘stop the spread.’ The pharmaceutical giant is now considering a “future vaccine relaunch.”

“BioNTech SE said on Friday it expects more data on a worrying new coronavirus variant detected in South Africa within two weeks to help determine whether its vaccine produced with partner Pfizer Inc would have to be reworked,” Reuters reported.

“Pfizer and BioNTech said that if necessary they expect to be able to ship a new vaccine tailored to the emerging variant in approximately 100 days,” the report added.

“We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529,” BioNTech said in a statement.

“We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,” it added.

“Moderna Inc said in a statement it is working to advance a booster candidate tailored to the new variant and has also been testing a higher dose of its existing booster and to study other booster candidates designed to protect against multiple variants,” the report continued.

"*" indicates required fields

Is the Mar-A-Lago raid an unjust witch hunt?*
This poll subscribes you to our premium network of content. Unsubscribe at any time.
This field is for validation purposes and should be left unchanged.

“A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity,” Moderna said in the statement.

“Those efforts are not meant to yield commercial products; the exercise is carried out to establish a routine with regulators that will help speed up any future vaccine relaunch,” Reuters noted.

Amid the reports of the Omicron variant, BioNTech ADRs gained 14.2% to close at $348 on Friday and Pfizer shares rose 6.1% to end at $54. Moderna gained 20.6% to close at $329.63.

The Pfizer-BioNTech vaccine is already under scrutiny for the waning efficacy of its mRNA prophylactic therapeutic, which has been marketed as a ‘vaccine’ for Covid-19. The pharmaceutic company, whose Comirnaty vaccine was ‘fully authorized’ for Covid-19 by the Food and Drug Administration was granted full liability shielding by the Biden administration. The so-called ‘vaccines’ have worn off so fast that the Centers for Disease Control is already recommending “boosters.”

Reuters reported that global authorities have reacted with alarm to the new variant, with the EU and Britain among those tightening border controls as scientists sought to find out if the mutation was vaccine-resistant. A new report indicates that more than 15 passengers on two flights from South Africa have tested positive for COVID-19 at Schiphol airport in Amsterdam.

A scientist who has been studying the Omicron variant described it as “horrific” in an interview with the BBC. Tulio de Oliveira, the director of South Africa’s Center for Epidemic Response and Innovation, told the BBC the variant has an “unusual constellation of mutations.” For example, the Delta variant had two mutations to its receptor binding domain; this variant has 10, he said.

Syndicated with licensed permission from Becker News. Follow Becker News on Telegram.

Notice: This article may contain commentary that reflects the author's opinion.